AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Shanghai Huaota Biopharmaceutical Co. logo
Shanghai Huaota Biopharmaceutical Co.Private
2 assets: 1 Ph 3, 1 Ph 2HB0034Phase 2/3 · PsoriasisNone on record————
Shanghai Huilun Pharmaceutical Co., Ltd. logo
Shanghai Huilun Pharmaceutical Co., Ltd.Private
1 asset: 1 Ph 2HL-1186Phase 2 · Diabetic Peripheral Neuropathic PainNone on record————
Shanghai JMT-Bio logo
Shanghai JMT-BioPrivate
4 assets: 2 Ph 3, 2 Ph 2BecotatugPhase 3 · Non-Small Cell Lung CancerPartial signal26 Mar 2027Becotatug · Phase 3————
Shanghai Juncell Therapeutics logo
Shanghai Juncell TherapeuticsPrivate
1 asset: 1 Ph 2GC101Phase 2 · Non-Small Cell Lung Cancer20 Dec 2026GC101 · Phase 1————
Shanghai Longwood Biopharmaceuticals logo
Shanghai Longwood BiopharmaceuticalsPrivate
2 assets: 1 Ph 3, 1 Ph 2LW402Phase 3 · Atopic DermatitisPartial signalMar 2027LW231 · Phase 1/2————
Shanghai Minwei Biotechnology logo
Shanghai Minwei BiotechnologyPrivate
1 asset: 1 Ph 1MWX205Phase 1 · Atherosclerotic Cardiovascular DiseaseNone on record————
Shanghai Simnova Biotechnology Co., Ltd. logo
Shanghai Simnova Biotechnology Co., Ltd.Private
2 assets: 2 Ph 1CART-BCMAPhase 1 · Multiple Myeloma31 Jan 2027F01 · Phase 1————
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd logo
Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdPrivate
1 asset: 1 Ph 2U32 CAR-TPhase 1/2 · Acute Myeloid Leukemia31 Dec 2027U32 CAR-T · Phase 1/2————
Shanghai UniXell Biotechnology Co., Ltd logo
Shanghai UniXell Biotechnology Co., LtdPrivate
3 assets: 1 Ph 2, 2 Ph 1UX-DA003Phase 1/2 · Parkinson's DiseaseDec 2027UX-DA001 · Phase 1————
Shanghai Vitalgen BioPharma Co., Ltd. logo
Shanghai Vitalgen BioPharma Co., Ltd.Private
2 assets: 2 Ph 2VGN-R08bPhase 1/2 · Parkinson's Disease1 Sep 2027VGN-R08b · Phase 1/2————
S
Shanghai Yinnuo Pharmaceutical TechnologyPrivate
1 asset: 1 Ph 3efsubaglutide alfaPhase 3 · Type 2 DiabetesReliable signal30 Apr 2027efsubaglutide alfa · Phase 1————
S
Shanxi Kangbao Biological ProductPrivate
2 assets: 2 Ph 2LipovirtidePhase 2 · HIVPartial signalNone on record————
Shenyang Sunshine Pharmaceutical logo
Shenyang Sunshine PharmaceuticalPrivate
5 assets: 3 Ph 3, 2 Ph 2Loncipoetin alfa (NuPIAO)Phase 3 · Chronic Kidney DiseasePartial signalDec 2026SSGJ-706 · Phase 2————
Shenzhen Forward Pharmaceuticals Co., Ltd. logo
Shenzhen Forward Pharmaceuticals Co., Ltd.Private
1 asset: 1 Ph 2FWD1802Phase 1/2 · HR+/HER2- Metastatic Breast Cancer1 May 2028FWD1802 · Phase 1/2————
Shenzhen Genocury Biotech Co., Ltd. logo
Shenzhen Genocury Biotech Co., Ltd.Private
1 asset: 1 Ph 1JY232Phase 1 · Multiple Myeloma31 Dec 2028JY232 · Phase 1————
Shenzhen Ionova Life Sciences Co., Ltd. logo
Shenzhen Ionova Life Sciences Co., Ltd.Private
2 assets: 2 Ph 2INV-6452Phase 1/2 · HR+/HER2- Metastatic Breast Cancer4 Feb 2028INV-6452 · Phase 1/2————
S
Shenzhen MingSight Relin PharmaceuticalsPrivate
1 asset: 1 Ph 2MS-553Phase 1/2 · Chronic Lymphocytic LeukemiaSep 2028MS-553 · Phase 1/2————
Shenzhen Pregene Biopharma Co., Ltd. logo
Shenzhen Pregene Biopharma Co., Ltd.Private
1 asset: 1 Ph 2BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2 · Multiple MyelomaWeak signalNone on record————
S
Shenzhen Sciprogen Bio-pharmaceuticalPrivate
1 asset: 1 Ph 2RD01 (PEG-EPO)Phase 2 · Chronic Kidney DiseasePartial signalNone on record————
Shenzhen TargetRx logo
Shenzhen TargetRxPrivate
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1DeulorlatinibPhase 3 · Non-Small Cell Lung CancerFeb 2027TGRX-1942 · Phase 1————
SHY Therapeutics logo
SHY TherapeuticsPrivate
1 asset: 1 Ph 1SHY-ONC6Phase 1 · Non-Small Cell Lung Cancer15 May 2027SHY-ONC6 · Phase 1————
S
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.Private
1 asset: 1 Ph 1BC008-1APhase 1 · Non-Small Cell Lung CancerNone on record————
Sichuan Purity Pharmaceutical Technology logo
Sichuan Purity Pharmaceutical TechnologyPrivate
1 asset: 1 Ph 2Arketamine (PRT042)Phase 2 · Major Depressive DisorderNone on record————
S
Simcere Zaiming Pharmaceutical Co., Ltd.Private
1 asset: 1 Ph 1SIM0505Phase 1 · Non-Small Cell Lung CancerFeb 2028SIM0505 · Phase 1————
Simcha IL-18, Inc. logo
Simcha IL-18, Inc.Private
1 asset: 1 Ph 2VevoctadekinPhase 1/2 · Non-Small Cell Lung CancerNone on record————
Sinotau Pharmaceutical Group logo
Sinotau Pharmaceutical GroupPrivate
1 asset: 1 Ph 2XTR003Phase 2 · Heart Failure31 Dec 2026XTR003 · Phase 2————
Sintetica logo
SinteticaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Siolta Therapeutics logo
Siolta TherapeuticsPrivate
1 asset: 1 Ph 2STMC-103HPhase 1/2 · Atopic DermatitisPartial signalNone on record————
Sirius Therapeutics logo
Sirius TherapeuticsPrivate
2 assets: 2 Ph 2SRSD107Phase 2 · Atherosclerotic Cardiovascular DiseaseDec 2027SRSD107 · Phase 2————
Sirtsei Pharmaceuticals logo
Sirtsei PharmaceuticalsPrivate
1 asset: 1 Ph 2ForvisirvatPhase 2 · Major Depressive DisorderPartial signalNone on record————
Solu Therapeutics, Inc logo
Solu Therapeutics, IncPrivate
1 asset: 1 Ph 1STX-0712Phase 1 · Acute Myeloid Leukemia31 Dec 2026STX-0712 · Phase 1————
Sorrento Therapeutics, Inc. logo
Sorrento Therapeutics, Inc.Private
1 asset: 1 Ph 2STI-6129Phase 1/2 · Multiple Myeloma31 Dec 2026STI-6129 · Phase 1/2————
Sorriso Pharmaceuticals logo
Sorriso PharmaceuticalsPrivate
1 asset: 1 Ph 1SOR102Phase 1 · Ulcerative ColitisWeak signalNone on record————
Sparrow Pharmaceuticals logo
Sparrow PharmaceuticalsPrivate
1 asset: 1 Ph 2clofutribenPhase 2 · Type 2 DiabetesWeak signal31 Dec 2027clofutriben · Phase 2————
S
Specialised TherapeuticsPrivate
1 asset: 1 Ph 3PlitidepsinPhase 3 · Multiple MyelomaPartial signalNone on record————
Spinogenix logo
SpinogenixPrivate
1 asset: 1 Ph 3Tazbentetol (SPG302)Phase 2/3 · Amyotrophic Lateral Sclerosis31 Dec 2027Tazbentetol (SPG302) · Phase 2/3————
SQ Innovation logo
SQ InnovationPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
STADA Arzneimittel logo
STADA ArzneimittelPrivate
6 assets: 3 approved, 2 Ph 3, 1 otherTrigelPhase 3 · Parkinson's DiseasePartial signalMar 2027Budesonide (targeted-release) · Approved————
Stelexis BioSciences logo
Stelexis BioSciencesPrivate
1 asset: 1 Ph 2EganelisibPhase 2 · Acute Myeloid Leukemia15 Dec 2027Eganelisib · Phase 1————
Stemline Therapeutics, Inc. logo
Stemline Therapeutics, Inc.Private
2 assets: 1 approved, 1 Ph 2TagraxofuspPhase 2 · Acute Myeloid LeukemiaWeak signalNov 2026Elacestrant · Phase 2————
Stendhal logo
StendhalPrivate
1 asset: 1 Ph 3GemigliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
Sulfateq B.V. logo
Sulfateq B.V.Private
1 asset: 1 Ph 2SUL-238Phase 2 · Parkinson's DiseaseNone on record————
S
Suninflam Inc.Private
1 asset: 1 Ph 1SIF001Phase 1 · Epilepsy15 Jan 2027SIF001 · Phase 1————
Suzhou Alphamab logo
Suzhou AlphamabPrivate
2 assets: 1 Ph 3, 1 Ph 2EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signalDec 2026Envafolimab · Phase 2————
S
Suzhou BlueHorse Therapeutics Co., Ltd.Private
1 asset: 1 Ph 2LM103Phase 2 · Non-Small Cell Lung Cancer31 Dec 2027LM103 · Phase 2————
Suzhou Genhouse Bio Co., Ltd. logo
Suzhou Genhouse Bio Co., Ltd.Private
1 asset: 1 Ph 2GH21Phase 2 · Non-Small Cell Lung CancerWeak signal30 Dec 2026GH21 · Phase 2————
Suzhou Immunofoco Biotechnology Co., Ltd. logo
Suzhou Immunofoco Biotechnology Co., Ltd.Private
1 asset: 1 Ph 1IMV102Phase 1 · Multiple Myeloma10 Dec 2027IMV102 · Phase 1————
S
Suzhou NeuPharma Co., Ltd.Private
1 asset: 1 Ph 2HLX208Phase 2 · Non-Small Cell Lung CancerWeak signalNone on record————
S
Suzhou Puhe BioPharma Co., Ltd.Private
1 asset: 1 Ph 2BAY 3713372Phase 1/2 · Non-Small Cell Lung Cancer18 Jun 2029BAY 3713372 · Phase 1/2————
Suzhou Puhe Pharmaceutical Technology Co., LTD logo
Suzhou Puhe Pharmaceutical Technology Co., LTDPrivate
2 assets: 1 Ph 3, 1 Ph 2PruvonertinibPhase 3 · Non-Small Cell Lung CancerNone on record————
Suzhou Sanegene Bio logo
Suzhou Sanegene BioPrivate
2 assets: 1 Ph 2, 1 Ph 1IBI3016Phase 2 · Hypertension30 Jan 2027IBI3016 · Phase 1————
Suzhou Siran Biotechnology logo
Suzhou Siran BiotechnologyPrivate
2 assets: 2 Ph 1SA030Phase 1 · Obesity30 Mar 2027SA1211 · Phase 1————
Syndeio Biosciences logo
Syndeio BiosciencesPrivate
2 assets: 2 Ph 2ZelquistinelPhase 2 · Major Depressive DisorderPartial signalSep 2027Zelquistinel · Phase 2————
SynDevRx, Inc. logo
SynDevRx, Inc.Private
1 asset: 1 Ph 2EvexomostatPhase 2 · HR+/HER2- Metastatic Breast CancerDec 2026Evexomostat · Phase 1/2————
Synphatec (Shanghai) Biopharmaceutical logo
Synphatec (Shanghai) BiopharmaceuticalPrivate
1 asset: 1 Ph 1SP-101Phase 1 · Major Depressive DisorderNone on record————
Synthekine logo
SynthekinePrivate
1 asset: 1 Ph 2STK-012Phase 1/2 · Non-Small Cell Lung CancerJan 2029STK-012 · Phase 1/2————
SystImmune logo
SystImmunePrivate
2 assets: 1 Ph 3, 1 Ph 1BL-M11D1Phase 2/3 · Acute Myeloid LeukemiaNone on record————
T
T's PharmaPrivate
2 assets: 1 Ph 3, 1 otherVoglibosePhase 3 · Type 2 DiabetesNone on record————
T3D Therapeutics logo
T3D TherapeuticsPrivate
1 asset: 1 Ph 3T3D-959Phase 2/3 · Alzheimer's DiseasePartial signalApr 2031T3D-959 · Phase 2/3————
Taiho Oncology logo
Taiho OncologyPrivate
1 asset: 1 approvedApproved assets onlyDec 2026Decitabine/cedazuridine (Inqovi) · Phase 1————
Taiho Pharmaceutical logo
Taiho PharmaceuticalPrivate
7 assets: 1 approved, 5 Ph 3, 1 Ph 2CasdatifanPhase 3 · Clear Cell Renal Cell CarcinomaMay 2027Casdatifan · Phase 1————
Taiwan Mitochondrion Applied Technology Co., Ltd. logo
Taiwan Mitochondrion Applied Technology Co., Ltd.Private
1 asset: 1 Ph 1MitoCellPhase 1 · Parkinson's Disease30 Sep 2027MitoCell · Phase 1————
Tanabe Pharma Corporation logo
Tanabe Pharma CorporationPrivate
12 assets: 7 approved, 4 Ph 3, 1 Ph 2TeneligliptinPhase 3 · Type 2 DiabetesReliable signalNov 2026Obicetrapib · Phase 3————
Taro Pharmaceutical Industries logo
Taro Pharmaceutical IndustriesPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Tasca Therapeutics logo
Tasca TherapeuticsPrivate
1 asset: 1 Ph 2CP-383Phase 1/2 · Non-Small Cell Lung Cancer15 Aug 2028CP-383 · Phase 1/2————
Tasly Biopharmaceuticals Co., Ltd. logo
Tasly Biopharmaceuticals Co., Ltd.Private
1 asset: 1 Ph 2T101Phase 2 · Chronic Hepatitis BNone on record————
TauRx Therapeutics logo
TauRx TherapeuticsPrivate
1 asset: 1 Ph 3Hydromethylthionine mesylatePhase 3 · Alzheimer's DiseasePartial signalNone on record————
T
Technoderma MedicinesPrivate
1 asset: 1 Ph 2TDM-180935Phase 2 · Atopic DermatitisPartial signalNone on record————
Teligene US logo
Teligene USPrivate
1 asset: 1 Ph 2SutetinibPhase 2 · Non-Small Cell Lung CancerDec 2027Sutetinib · Phase 2————
T
Tenacia BiotechnologyPrivate
1 asset: 1 Ph 3RAP-219Phase 3 · EpilepsyWeak signalJun 2027RAP-219 · Phase 1————
TerSera Therapeutics LLC logo
TerSera Therapeutics LLCPrivate
2 assets: 2 approvedApproved assets only30 Mar 2027Goserelin · Phase 1————
Theracos logo
TheracosPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
TherAguix logo
TherAguixPrivate
1 asset: 1 Ph 2AGuIXPhase 1/2 · Non-Small Cell Lung CancerNone on record————
Theratechnologies logo
TheratechnologiesPrivate
4 assets: 4 approvedApproved assets onlyDec 2026Donidalorsen · Phase 3—$16MNov 2024Ended May 2025—
Theravia logo
TheraviaPrivate
1 asset: 1 approvedApproved assets onlyFeb 2028Hydroxyurea (Siklos) · Phase 2————
Therini Bio, Inc. logo
Therini Bio, Inc.Private
1 asset: 1 Ph 1THN391Phase 1 · Alzheimer's Disease31 Mar 2027THN391 · Phase 1————
Thryv Therapeutics logo
Thryv TherapeuticsPrivate
1 asset: 1 Ph 1THRV-1268Phase 1 · Heart FailureWeak signal30 Jun 2027THRV-1268 · Phase 2/3————
Tianjin Hemay Pharmaceutical logo
Tianjin Hemay PharmaceuticalPrivate
2 assets: 1 Ph 3, 1 Ph 1MufemilastPhase 3 · Ulcerative ColitisPartial signalNone on record————
T
Tianjin SinoBiotechPrivate
1 asset: 1 Ph 2Human Serum Albumin/interferon alpha2b fusion proteinPhase 1/2 · Chronic Hepatitis BNone on record————
T
Tillotts Pharma AGPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
TILT Biotherapeutics Ltd. logo
TILT Biotherapeutics Ltd.Private
1 asset: 1 Ph 1Igrelimogene litadenorepvecPhase 1 · Non-Small Cell Lung CancerNov 2026Igrelimogene litadenorepvec · Phase 1————
T
Timberlyne TherapeuticsPrivate
1 asset: 1 Ph 3LumrotatugPhase 3 · Multiple MyelomaWeak signalMar 2027Lumrotatug · Phase 2————
TJ Biopharma Co., Ltd. logo
TJ Biopharma Co., Ltd.Private
3 assets: 2 Ph 3, 1 Ph 2Efmedaglutide alfaPhase 3 · ObesityPartial signal5 Aug 2028Uliledlimab · Phase 2/3————
T
ToLymph Inc.Private
1 asset: 1 Ph 2Paclitaxel (SMS001)Phase 2 · Non-Small Cell Lung CancerNone on record————
Torii Pharmaceutical logo
Torii PharmaceuticalPrivate
1 asset: 1 approvedApproved assets onlyAug 2027Tapinarof · Phase 3————
TORL Biotherapeutics, LLC logo
TORL Biotherapeutics, LLCPrivate
1 asset: 1 Ph 2Ixotatug vedotinPhase 2 · Ovarian CancerOct 2027Ixotatug vedotin · Phase 2————
Treadwell Therapeutics, Inc logo
Treadwell Therapeutics, IncPrivate
1 asset: 1 Ph 2OcifisertibPhase 1/2 · Acute Myeloid LeukemiaWeak signalNone on record————
TRex Bio logo
TRex BioPrivate
1 asset: 1 Ph 1TRB-061Phase 1 · Atopic Dermatitis2 Sep 2027TRB-061 · Phase 1————
TriGemX Bio logo
TriGemX BioPrivate
1 asset: 1 Ph 3ElismetrepPhase 3 · MigraineFeb 2027Elismetrep · Phase 3————
Triveni Bio logo
Triveni BioPrivate
1 asset: 1 Ph 2TRIV-509Phase 2 · Atopic DermatitisNone on record————
TrueBinding, Inc. logo
TrueBinding, Inc.Private
1 asset: 1 Ph 2TB006Phase 2 · Parkinson's Disease28 Nov 2026TB006 · Phase 2————
TrueLab Biopharmaceutical logo
TrueLab BiopharmaceuticalPrivate
1 asset: 1 Ph 1TL-003Phase 1 · Ulcerative ColitisApr 2027TL-003 · Phase 1————
Tubulis GmbH logo
Tubulis GmbHPrivate
1 asset: 1 Ph 2TUB-030Phase 1/2 · Non-Small Cell Lung CancerNone on record————
Twinpig Biolab, Inc. logo
Twinpig Biolab, Inc.Private
1 asset: 1 Ph 2TB511Phase 1/2 · Non-Small Cell Lung CancerMar 2027TB511 · Phase 1/2————
Tyligand Pharmaceuticals (Suzhou) Limited logo
Tyligand Pharmaceuticals (Suzhou) LimitedPrivate
1 asset: 1 Ph 2TSN1611Phase 1/2 · Non-Small Cell Lung Cancer30 Oct 2027TSN1611 · Phase 1/2————
Umoja Biopharma logo
Umoja BiopharmaPrivate
1 asset: 1 Ph 1UB-VV500Phase 1 · Multiple Myeloma31 Dec 2029UB-VV500 · Phase 1————
UNION Therapeutics logo
UNION TherapeuticsPrivate
1 asset: 1 Ph 2orismilastPhase 2 · Atopic DermatitisReliable signalNone on record————
U
United Bio-Technology (Hengqin)Private
2 assets: 1 Ph 3, 1 Ph 1UBT251Phase 3 · ObesityDec 2026UBT251 · Phase 1————
United BioPharma logo
United BioPharmaPrivate
1 asset: 1 Ph 3SemzuvolimabPhase 3 · HIVWeak signalNone on record————
U
US WorldMeds, LLCPrivate
2 assets: 1 approved, 1 Ph 2letetresgene autoleucelPhase 2 · Myxoid/Round Cell LiposarcomaWeak signalNone on record————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415